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the pharmaceutical solvent 
N‑methyl‑2‑pyrollidone (NMP) 
attenuates inflammation 
through Krüppel‑like factor 2 
activation to reduce atherogenesis
Marta Roche‑Molina1,8, Bryn Hardwick2,8, Cristina Sanchez‑Ramos1, David Sanz‑Rosa1,3,4, 
Dirk Gewert5, Francisco M. Cruz1, Andres Gonzalez‑Guerra1, Vicente Andres1,3, 
Joaquin A. Palma6, Borja Ibanez1,3,7, Grahame Mckenzie2* & Juan A. Bernal1,3*
N‑methyl‑2‑pyrrolidone (NMP) is a versatile water‑miscible polar aprotic solvent. It is used as a drug 
solubilizer and penetration enhancer in human and animal, yet its bioactivity properties remain 
elusive. Here, we report that NMP is a bioactive anti‑inflammatory compound well tolerated in vivo, 
that shows efficacy in reducing disease in a mouse model of atherosclerosis. Mechanistically, NMP 
increases the expression of the transcription factor Kruppel-like factor 2 (KLF2). Monocytes and 
endothelial cells treated with NMP express increased levels of KLF2, produce less pro‑inflammatory 
cytokines and adhesion molecules. We found that NMP attenuates monocyte adhesion to endothelial 
cells inflamed with tumor necrosis factor alpha (TNF‑α) by reducing expression of adhesion molecules. 
We further show using KLF2 shRNA that the inhibitory effect of NMP on endothelial inflammation and 
subsequent monocyte adhesion is KLF2 dependent. Enhancing KLF2 expression and activity improves 
endothelial function, controls multiple genes critical for inflammation, and prevents atherosclerosis. 
Our findings demonstrate a consistent effect of NMP upon KLF2 activation and inflammation, 
biological processes central to atherogenesis. Our data suggest that inclusion of bioactive solvent 
NMP in pharmaceutical compositions to treat inflammatory disorders might be beneficial and safe, in 
particular to treat diseases of the vascular system, such as atherosclerosis.
Atherosclerosis poses a significant burden to healthcare systems throughout the world. Without access to new, 
inexpensive treatments, atherosclerosis and its associated cardiovascular complications will likely remain a 
leading cause of morbidity and mortality  worldwide1. A compelling body of evidence now describes the impor-
tance of endothelial dysfunction and inflammation during the development of  atherosclerosis2, evidence which 
has driven the pharmaceutical industry to target inflammatory pathways in the quest for novel therapeutic 
 strategies3–5. The classical view states that the initial step of inflammation during atherosclerosis depends on the 
activation of the vascular  endothelium6. It is now evident that biomechanical forces exerted upon the endothelial 
layers by blood flow play a significant role in the resolution of inflammatory  insults7,8. Gene expression studies 
have demonstrated major differences in the transcriptional profile exerted upon the endothelium by a healthy, 
laminar blood flow compared to the complex and turbulent flow associated with early sites of atherosclerotic 
 lesions6,9,10. These studies have been extensively recapitulated in in vitro studies on endothelial cell monolayers 
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under shear stress  conditions11. The consistent message coming out from such studies is that a healthy blood flow 
provokes an endothelial transcriptional program characterized by increased expression of anti-inflammatory, 
anti-adhesive and anti-thrombotic  factors6,12. Of the many factors identified, the zinc finger transcription factor 
Krüppel-like factor (KLF2)13 has emerged as a master regulator of the atheroprotective transcriptional program 
in the  endothelium14,15 and in various myeloid-derived cell  types16,17. High-shear stress at the endothelial surface 
induces KLF2, reducing inflammatory activation and antithrombotic  properties18–20. Crucially, these studies 
underline the active role of the endothelial cells and leukocytes as key regulators of vascular function to main-
tain vascular  homeostasis6,21,22. Modified lipoproteins accumulation in the subendothelial space aggravates the 
endothelial cell dysfunction and results in the accumulation of macrophages derived from circulating monocytes 
in the arterial  wall23–25. Inflammatory activation of macrophages triggers the secretion of inflammatory cytokines, 
such as tumour necrosis factor-α (TNF-α), which further promotes endothelial maladaptation by activating 
NF-κB26,27. It has been also shown that KLF2 plays a critical role in regulating proinflammatory activation in 
 monocytes22. Such studies provide a striking case for KLF2-enhancing therapies as treatment for atherosclerosis, 
a disease whose etiology is a direct consequence of inflammation and disrupted vascular  hemodynamics3,28. Such 
a hypothesis is supported by the observation that the statin class of anti-atherosclerotic drugs function at least 
partly through their ability to increase KLF2  expression28,29.
N-Methyl-2-pyrrolidone (NMP) is a polar aprotic solvent that is frequently used in industrial and pharmaceu-
tical  settings30. NMP is remarkably effective in maintaining dispersions of different types of  nanomaterials31–33. 
Given its safety profile at established  doses30,34 and its competence to solubilize multiple types of drugs, NMP has 
become a common solvent component of in situ forming  implants35–37, for long-term drug  delivery38,39. NMP 
acts as a co-solvent and as a complexing agent in different embodiments as it has been reported to increase the 
solubility and permeability of multiple  compounds36,40–42. Transcriptional activity of bromodomain-containing 
proteins is compromised by NMP interaction with the binding pocket of a different bromodomains, what would 
contribute to its anti-myeloma and immunomodulatory  activity43.
In this study, we describe an unexpected effect of the FDA-approved solvent NMP upon KLF2 expression. 
NMP enhances expression of KLF2 at the transcriptional level by activating the KLF2 promoter. Consequently, 
NMP displays a consistent range of anti-inflammatory effects upon myeloid and endothelial cells in vitro, oppos-
ing TNF-α-mediated inflammatory cytokine production and surface adhesion molecule expression. We confirm 
these observations in an in vivo setting, where NMP inhibits disease progression in a murine model of athero-
sclerosis. Finally, we demonstrate that these effects also extend to ex vivo human leukocytes, where NMP inhibits 
leukocyte adhesion to an endothelial layer. As an FDA-approved solvent with a well-established safety profile, 
NMP may represent a unique opportunity for expedited clinical development for atherosclerosis, especially as 
a supportive compound to be used in combination with existing therapeutic agents.
Results
NMP activates Klf2 transcription. Previous studies have demonstrated that NMP can affect stem cell dif-
ferentiation by promoting Bone Morphogenic Protein (BMP)-dependent  responses44. In order to ascertain the 
mechanism by which NMP influences these processes, we established a system in the murine C2C12 cell line, 
which differentiates in response to  BMP245. As previously reported, NMP potentiated BMP2-dependent differ-
entiation in this system (data not shown). We further investigated the mechanism by which this might occur by 
performing transcriptional profiling using mouse genome survey microarrays. A cursory analysis of the results 
revealed an effect of NMP on the expression of Klf2. In these microarray experiments, NMP enhanced expres-
sion of Klf2 after 8 h of treatment (Fig. 1a). This observation was confirmed by Q-PCR analysis from independ-
ent experiments (Fig. 1b). The importance of Klf2 in  atheroprotection14 led us to investigate this serendipitous 
effect further.
Reasoning that this increase in Klf2 might be due to transcriptional activation, we investigated whether NMP 
could affect the activity of the Klf2 promoter. To address this question, we cloned the mouse Klf2 promoter 
upstream of a firefly luciferase reporter with an upstream adenoviral TATA box. Transient transfection of this 
construct into C2C12 cells showed that the putative Klf2 promoter drove a significant luciferase activity over 
and above that of the vector lacking a promoter, confirming its identity as regulatory element. NMP treatment 
was able to transactivate the Klf2 promoter construct in a time-dependent manner (Fig. 1c), confirming the 
microarray and Q-PCR data. Furthermore, this transactivation activity of NMP over the Klf2 promoter was 
Figure 1.  Bioactive NMP is a Klf2 transcriptional activator. (a) Microarray analysis showing top 10 genes 
up regulated in C2C12 cells by addition of 5 mM NMP for 8 h. (b) Real-time PCR analysis of Klf2 mRNA in 
mouse C2C12 cells at different time points after NMP administration. Klf2 mRNA amounts are normalized 
to Gapdh mRNA and are presented relative to the level observed in untreated cells. Data are presented as 
mean ± SEM; n = 6. (c) C2C12 cells transfected with a luciferase Klf2-promoter reporter analyzed at different 
time points w/wo NMP (1 mM). The luciferase activity was measured and normalized to Renilla activity, and 
represented in arbitrary units (AU) from two independent assays (n = 6). (d) MEF and MAEC cells transfected 
as in (c) were treated with or without NMP. Luciferase assays were performed 24 h after transfection. Data are 
presented as mean ± SEM; n = 5 *** p < 0.001 (one-way ANOVA with the Bonferroni comparison post-test). (e) 
TNF-α mediated (10 ng/ml) inhibition of Klf2 mRNA is suppressed by NMP (1 mM). Data are presented as 
mean ± SEM; n = 6, ns p > 0.05, *** p < 0.001, one-way ANOVA. (f) NMP pretreatment for 6 h protects against 
cell death induced in C2C12 cells activated with TNF- α for 24 h (n = 6; ***p < 0.001, one-way ANOVA with the 
Bonferroni comparison post-test).
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not cell type specific, as we could observe activation in mouse embryonic fibroblast (MEF) and mouse aortic 
endothelial cells (MAEC) (Fig. 1d).
We asked whether NMP’s effect on Klf2 transcription has a functional effect downstream. Pro-inflammatory 
cytokines have been reported to down-regulate Klf2  expression46. We confirmed this in C2C12 cells: TNF-α 
treatment decreased Klf2 mRNA levels as measured by Q-PCR, but this effect was overcome in the presence of 
NMP, leading to the maintenance of Klf2 mRNA levels (Fig. 1e). This ability of NMP to oppose TNF-α-mediated 
reduction of Klf2 mRNA was correlated with increased cell viability (Fig. 1f), where NMP treatment markedly 
inhibited the ability of TNF-α to kill C2C12 cells.
To determine whether Klf2 regulates the transcriptional program that drives survival of C2C12 cells after 
TNF-α administration, we used lentiviral shRNA construct to down-regulate Klf2. QPCR analysis confirmed 
that Klf2-specific shRNA effectively suppressed Klf2 expression in cells, whereas a control shRNA had no effect 
(Fig. 2a). We determined that shRNA-mediated Klf2-knockdown effectively suppresses transcription of target 
genes like Vcam-1 (Fig. 2b), and found that NMP protective effect after TNF-α treatment on survival of C2C12 
is Klf2-specific. Klf2 shRNA knockdown substantially reduced the cell survival after co-administration of TNF-α 
and NMP, whereas the control shRNA had no significant effect (Fig. 2c). These data strongly suggest that NMP 
treatment provokes effects which oppose pro-inflammatory responses and cell survival in cell-based assays.
NMP is tolerated and increases Klf2 expression in vivo. We reasoned that NMP’s status as an FDA-
approved pharmaceutical excipient might make it an attractive solvent with intrinsic therapeutic activities for 
treating atherosclerosis. Given the in vitro effects of NMP described above, combined with its favorable safety 
profile, we tested its in vivo efficacy. We first confirmed previous safety assessments of  NMP34,47. Adult C57BL6/J 
mice (8–12 weeks old) were injected i.v. or i.p. with NMP at 25, 125 and 250 mg/kg, and sacrificed twenty four 
hours after treatment. Histopathology was performed and analyzed for macroscopic alterations in liver, heart, 
kidney, spleen, gut, skeletal muscle, and lung to study the effects of NMP: no inflammation, fibrosis or necrosis 
were seen at any doses. In addition, serum levels of alanine aminotransferase (ALT) were evaluated as a marker 
for potential metabolic hepatocellular injury. We observed no differences in ALT levels between NMP- and 
saline-treated mice (Supplementary Fig. 1a). To confirm a transcriptional effect of NMP in vivo, we adminis-
tered NMP at 25, 125 and 250 mg/kg intravenously and prepared total RNA from liver 24 h post-treatment. Klf2 
mRNA levels after NMP administration were increased in a dose-dependent manner compared with saline-
treated animals (Fig. 3a). In addition to Klf2, we noted that NMP treatment caused a decrease in Cxcl12 (Fig. 3b) 
and Vcam-1 (Fig. 3c) mRNA expression. The Cxcl12 promoter region has previously been shown to be repressed 
by  KLF248.
Since mouse models of atherosclerosis develop over a prolonged period, we also tested the tolerability of long-
term NMP treatment based on previous  work47. NMP was administered in drinking water at 0.75 mg/ml (150 mg/
kg/day)47 to mice fed a high-cholesterol diet for a 12-week period. No evidence for differential hepatocellular 
NMP - - +
shRNA Klf2 - + +
+
-
0
2
4
6
- - +
- + +
+
-
***
**
***
*** ***
ns
ns
***
ns
*** ***
ns
*
ns
***
ns
***
***
m
R
N
A 
K
lf2
 x
fo
ld
m
R
N
A 
V
ca
m
-1
 x
fo
ld
a b c
NMP
shRNA Klf2
0
1
2
3
4
0
20
40
60
80
100
120
TNF-α
- +
- +-
- + +
-
+
+-NMP
shRNA Klf2
%
 liv
e 
ce
lls
Figure 2.  NMP ameliorates TNF-α-induced-apoptosis through the Klf2 pathway. (a) Exponentially growing 
non-synchronized cells were transduced with lentiviral particles encoding for shRNA against KLF2 mRNA 
(“shRNA”) or for a non-specific shRNA as control; 72 h after infection cells stimulated with TNF- α for 6 h 
were exposed to NMP (1 mM), RNA was purified and Klf2 (a) and Vcam-1 (b) mRNA levels were analyzed by 
QPCR, and (c) cell viability was measured by flow cytometry. The results in C2C12 cell line show at least two 
independent biological replicates (n = 6). Error bars represent the standard error of the means (SEM). Significant 
differences are represented by asterisks: *p < 0.05, **p < 0.01 and ***p < 0.001, or non-significant (ns), by one-way 
ANOVA with Bonferroni’s multiple comparison test.
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damage between the groups was observed (Supplementary Fig. 1b). Taken together these data demonstrate that 
NMP can enhance Klf2 expression and its associated downstream pathways in vivo.
NMP treatment increases atheroprotection in HFD‑fed ApoE−/− mice. Having shown that NMP 
exerts an anti-inflammatory effect in cultured cells and that it is also well tolerated and active in vivo, we tested 
NMP in an animal model of atherosclerosis. The hypercholesterolemic apolipoprotein-E-deficient (ApoE−/−) 
mouse, when fed with a high fat diet (HFD) is used as a standard model of  atherosclerosis49. To assess ath-
erosclerotic plaque development after long-term NMP treatment, HFD-fed mice were allowed access to either 
untreated drinking water, or drinking water containing 0.75 mg/ml NMP for a period of 12 weeks. At the end of 
this treatment period, mice were euthanized and their aortas analyzed for signs of atherosclerosis. Histological 
analysis of en face-prepared aortas stained with Oil Red O (Fig. 4a) demonstrated a reduction in atherosclerotic 
area in aortic arch of NMP-treated mice (Fig. 4b). As shown by Oil Red O, NMP treatment led to a decrease in 
the size of atherosclerotic plaques in the aortic arches of HFD-fed ApoE−/− mice. Quantitative image analysis of 
the total area of atherosclerotic lesions (Fig. 4c) showed a significant effect of NMP treatment. Further histologi-
cal analysis at the aortic sinus also demonstrated that NMP treatment had reduced the mean aortic root lesion 
area compared with untreated HFD-fed ApoE−/− mice (Fig. 4d).
To characterize the effects of NMP on atherosclerotic lesions, we stained aortas for various inflammatory 
markers and analyzed their expression by immunofluorescence (Fig. 5a). Vcam-1 staining was markedly reduced 
with NMP treatment, and, consistent with this, macrophage infiltration into sites of atherosclerosis, as assessed 
with CD68 staining, was also significantly reduced. Our staining also showed that NMP administration inhibited 
Vcam-1 induction (Fig. 5b,c) in the alpha-actin-2 (α-SMA) smooth muscle  cells50 present at the atherosclerotic 
lesions. These results confirmed that NMP treatment has a striking inhibitory effect upon the inflammatory 
status of the aorta during atherogenesis.
NMP attenuates expression of inflammation genes in the aorta. Klf2 expression in this location 
plays a key atheroprotective role, preventing local inflammation and the subsequent formation of atherosclerotic 
lesions. We therefore tested whether NMP administration could influence gene expression in the aortic arch. 
To this end, ApoE−/− mice were fed with HFD and treated with or without NMP, which was formulated in the 
drinking water (0.75 mg/ml). Mice were sacrificed after 12 weeks and total RNA was extracted from the aortic 
arch (Fig. 6a) to study the transcriptome of the aortic arches in these mice. Klf2 mRNA analysis revealed an 
induction of expression in aortas of NMP-treated mice (Fig. 6b). In a pilot experiment, we next compared the 
global expression profiles of ApoE−/− controls with ApoE−/− mice treated with NMP (n = 2 for each groups) using 
next-generation sequencing (NGS). We performed hierarchical clustering on 1 logarithmic fold change of the 
significant altered genes (p < 0.05) between the two experimental groups. The resulting dendrogram showed that 
co-segregation occurred entirely according to sample type, with a clear division between control- and NMP-
treated mice (Fig. 6c). Given the strong consistency and reduced variability between duplicated samples we were 
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Figure 3.  NMP is bioactive in vivo. (a) Real-time PCR analysis in liver samples of mRNA expression of (a) 
Klf2 mRNA in mice treated with 25, 125 and 250 mg/kg of NMP. ***p < 0.001, **p < 0.005,*p < 0.01 by one-way 
ANOVA with Bonferroni’s multiple comparison test (n = 5 mice). Each data point denotes a liver sample from 
an individual mouse. (b,c) endogenous mouse Cxcl12 and Vcam-1 mRNA in treated mice with 25 mg/kg mouse. 
mRNA amounts are normalized to Gapdh mRNA relative to the level of liver samples in non-treated animals. 
(n = 5; ***p < 0.001, unpaired Student’s t test).
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Figure 4.  NMP attenuates atherosclerosis development in ApoE − / − mice. (a) Representative en face Oil Red O 
staining of aortas from treated and untreated NMP mice maintained on HFD for 12 weeks. (b) Representative 
Masson’s trichrome (upper panel) and Oil Red O (lower panel) staining in aortic root sections from HFD-fed 
NMP treated and untreated mice. Scale bar, 200 μm. (c) Quantitative analysis of atherosclerotic lesion size in Oil 
Red O-stained in aortic arch region from (a). (d) Quantitative analysis of atherosclerotic lesion size in Oil Red 
O-stained aortic sections from (c). (n = 12–18; *p < 0.01, **p < 0.005, unpaired Student’s t test).
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Figure 5.  NMP treatment reduces macrophages infiltration and inflammation. (a) Representative 
immunostaining of macrophages, smooth muscle cells (SMC) and activated endothelium in aortic sinus lesions 
of NMP treated and untreated C57BL/6 J mice fed with HFD for 12 weeks. Lesions were stained for biomarkers 
of macrophages (CD68; yellow), SMCs (α-actinin; green) and stressed endothelium (Vcam-1; red); nuclei were 
stained with DAPI (blue). Merged images are also shown. Lm, aortic lumen, M, tunica media, and I, tunica 
intima. White dashed lines demarcate the elastic lamina. Bars, 200 μm. (b) Vcam-1 and merge staining as in 
(a) from different animals. (c) Quantitative analysis of relative Vcam-1 immunostaining relative to the aortic 
sections size from (b).
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able to perform an unsupervised transcriptomic assessment to detect differential alterations in a total of 448 
genes, using a cut-off of twofold (Supplementary Table 2). Unbiased Ingenuity Pathway Analysis (IPA) of the 
molecular and cellular functions of these differentially expressed genes (threshold p < 0.05) identified 5 major 
networks that were differentially affected by NMP treatment (Fig. 6d). The most significant alterations in func-
tional networks were related to genes involved in the immune response, specifically leukocyte adhesion and 
extravasation. The list of down-regulated transcripts included a striking number of pro-inflammatory factors 
and adhesion molecules such as CD5L, Ptgs2 (also known as Cox-2), Vcam-1, Sele, Psgl-1, Selplg, several integrins 
(Itgal, Itgax, Itga6, Itgb2)51 and chemokine receptors (Ccr2, Ccr5)52, many of which are known to play a key role 
in leukocyte adhesion to the endothelium. Other genes involved in vascular homeostasis and tone (End-1 and 
Nos2), blood clot dissolution (Serpine-1) and lipid metabolism (Olr1) were also down-regulated. There were also 
up-regulated transcripts of interest, notably Apoa253, which controls reverse cholesterol transport, and Ptx354 
a regulator of monocyte differentiation and trafficking. This initial unbiased transcriptomic approach suggests 
that NMP exerts a dramatic anti-inflammatory effect upon the aortic arch of atherosclerotic mice.
NMP is active in human monocytes and endothelial cells. Our in vivo data in an established murine 
model of atherosclerosis drove our study towards human cells. For these experiments, we utilized human 
THP‐155 monocyte and umbilical vein endothelial cells (HUVECs), which are widely accepted as an appropriate 
proxy for their in vivo counterparts in the human  vasculature56. We treated THP‐1 and HUVECs with NMP 
and measured KLF2 transcript by Q-PCR. As seen in murine cells and in vivo, NMP caused an increase in KLF2 
messenger levels in HUVEC and TPH-1 cells that peaked 4 h after treatment (Fig. 7a,b). We then attempted to 
correlate this increase in KLF2 with downstream functional effects. High levels of KLF2 expression in HUVECs 
have been previously associated with a state of functional quiescence, characterized by non-responsiveness to 
inflammatory stimuli such as IL-1 and TNF-α57. We therefore hypothesized that NMP would oppose the effects 
of inflammatory insults to monocytes and endothelial cells. THP‐1 monocyte and HUVECs cells were pre-
incubated for 24 h with stealth siRNA targeting human KLF2 specific siRNA or scramble control before treating 
them with the inflammatory cytokine TNF-α. To test whether NMP activity on TNF-α is KLF2-dependent, 
Ascending
aorta
Arch
Descending
thoracic aorta
RNA extraction3mm
d
a b
Leukocyte extravasation signaling  3.97E-11 24/201 (0.119)
Dendritic cell maturation   4.1E-11 23/207 (0.111)
Primary Immunodeficiency signaling  2.78E-9 12/62 (0.194)
Atherosclerosis signaling   4.28E-9 17/136 (0.125)
Fcγ receptor-mediated phagocytosis  5.73E-9 15/102 (0.147)
in macrophages and monocites   
Top canonical pathway   p-value ratio
NMP Saline
Color key
-2 -1 0 1 2
0.0
0.5
1.0
1.5
2.0
Sa
lin
e
NM
P
K
LF
2
m
R
N
A 
re
la
tiv
e 
le
ve
l
*
c
Figure 6.  Gene expression signature of NMP treatment in the atherosclerotic aorta. (a) The diagram shows the 
aortic section plane (red line) and the aortic tissue sampled for RNA-seq studies. (b) Real-time PCR analysis 
of Klf2 mRNA in aortic arches after NMP or saline administration. Klf2 mRNA amounts are normalized to 
Gapdh mRNA and are presented relative to the level observed in untreated aortas. (c) Heat map of top genes 
differentially expressed in aortic arches between NMP and saline treated mice. Scaled expression values are 
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differentially expressed genes. The top bar indicates the treatment: light blue, NMP; blue, saline control. (d) Top 
canonical pathways that were significantly deregulated by NMP treatment, as identified by Ingenuity Pathway 
Analysis. The significance of association between altered genes and the canonical pathway was assessed using a 
right-tailed Fisher’s exact test to calculate a p value determining the probability that the association is explained 
by chance alone. Ratios defining the proportion of deregulating genes from a pathway related to the total 
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Figure 7.  NMP inhibits TNF-α-dependent vascular inflammation by KLF2. (a) Real-time PCR analysis of 
KLF2 mRNA in human HUVEC and (b) THP-1 cells after 24 h of NMP administration. KLF2 mRNA amounts 
are normalized to GADPH mRNA and are presented relative to the level observed in untreated cells. (c) 
Percentage of VCAM-1 positive HUVEC cells. NMP reduces cytokine release in HUVEC cells after TNF-α 
stimulation. Supernatants from HUVEC cells were harvested after 24 h of treatment, and the concentration of 
MCP-1 (c) and IL-6 (d) measured by ELISA, TNF-α treated with NMP compared with TNF- α untreated cells. 
(f) Real-time PCR analysis of PTGS2 mRNA in human THP-1 cells. All data is shown as mean ± SEM (n = 4–7). 
*p < 0.01, **p < 0.005, ***p < 0.001 by one-way ANOVA with Bonferroni’s multiple comparison test.
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activated cells with or without KLF2 were incubated at the same time with NMP. After additional 24 h, cel-
lular response was assessed by two parameters in HUVEC cells: expression of the surface marker VCAM-1, 
and production of the pro-inflammatory cytokines MCP-1/CCL2 and IL-6, and PTGS2 in THP-1 monocytes. 
As shown in Fig. 7c,d,e,f respectively, NMP had a profound effect upon VCAM-1 surface expression MCP-1/
CCL2 and IL-6 secretion, dramatically opposing the effect of TNF-α. Equivalently, we observed an inhibition of 
PTGS2 in cultured monocytes incubated with NMP. However, THP‐1 monocyte and HUVECs cells treated with 
KLF2-directed siRNAs partially lost the effect of NMP on TNFα‐induced response. These results correlate with 
the loss of activation of known KLF2 targets like VCAM-1 in HUVEC cells, and PTGS2 in THP-1 monocytes. 
These data demonstrate that anti-inflammatory effect of NMP is KLF2-dependent. Furthermore, NMP is not 
effective only upon mouse cells but indeed has a robust protective effect upon human monocytes and vascular 
endothelial cells.
NMP prevents monocyte adhesion. Monocyte adhesion and extravasation from the circulatory system 
into sites of endothelial cell inflammation is central to atherogenesis. We therefore hypothesized that VCAM-1 
down-regulation induced by NMP could be critical to reduce monocyte recruitment and firm adhesion to a 
dysfunctional human endothelial layer. To analyze a potential VCAM-1 regulated interaction of endothelial cells 
and monocytes/macrophages, we first performed static adhesion assays using endothelial cells and the THP-1 
monocyte cell line. Both control and KLF2 siRNA treated HUVECs were stimulated with soluble TNF-α and 
treated or not with NMP. We found that stimulation of HUVECs with TNF-α for 6 h significantly enhances 
subsequent adhesion of THP-1 cells (Supplementary Fig. 2), that it is diminished by NMP treatment in a KLF2-
dependent manner. In contrast, KLF2 knockdown alter THP-1 cell adhesion compared to HUVECs treated with 
scramble control. The extent of enhancement of THP-1 cell adhesion to HUVECs induced by KLF2 siRNA is 
comparable to that of TNF-α. Increased monocyte adhesion to endothelial cells induced by TNF-α is known to 
be important during the initiation of an atherosclerotic lesion.
To test the ability in a more dynamic scenario we established an in vitro shear stress flow system to test 
leukocyte adhesion to an endothelial cell layer measured under flow  conditions58. In the first of these experi-
ments, HUVEC cells were cultured upon µ-Slide  VI0.4 flow chambers, and then the human monocytic cell line 
THP-1 was added to this monolayer in media containing either TNF-α alone, or TNF-α plus NMP. After 6 h of 
incubation, re-circulating flow was applied to the flow chamber at 5 dyn/cm2, and video images were captured 
for 3 min. The results of this experiment are shown in Supplementary Movies 1 and 2, and snapshots taken at 
different time points from these videos are shown in Fig. 8a. THP-1 cells clearly remain adhered to the HUVEC 
monolayer in the presence of TNF-alpha alone, including NMP in the media minimizes THP-1 adhesion, and 
the cells are clearly washed from the HUVEC monolayer with flow. These observations are quantified in Fig. 8b. 
NMP therefore prevents a model monocyte cell line from adhering to activated human endothelial cells.
To extend this experiment, we once again employed a flow system, but this time used peripheral blood mono-
nuclear cells (PBMCs). HUVECs were plated in µ-Slide  VI0.4 flow chambers and then treated for 6 h with media 
containing either TNF-α alone, or TNF-α plus NMP to activate the endothelium. Freshly-isolated PBMCs were 
then applied to the flow chamber with re-circulation. After 10 min of 5 dyn/cm2 of flow, the slides were fixed 
for immunofluorescent analysis. As shown in (Fig. 8c), NMP treatment inhibited TNF-α-dependent VCAM-
1 expression (quantified in Fig. 8d) and, crucially, inhibited the number of leukocytes (as measured with the 
pan-leukocyte marker CD11b) able to adhere to the activated endothelial layer (Fig. 8e). Taken together, these 
data demonstrate that, under our model flow assay, NMP opposes the effects of inflammation upon leukocyte 
retention and binding to endothelial cell layers, a process which is a key event in the establishment of initial 
atherosclerotic lesions.
Discussion
NMP is a common solvent with extensive industrial uses. Its superior solvent properties, combined with its 
favorable in vivo tolerability and safety profile, have led to its use as a pharmaceutical excipient in a wide range 
of current  therapies30. Most notably, it is used in the formulation for a number of clinical oncology  compounds43. 
Long assumed to be inert, recent data has shown that NMP exerts dramatic effects in a murine model of mul-
tiple myeloma, possibly through its ability to function as an acetyl-lysine mimetic, inhibiting bromodomain-
containing proteins such as  BRD443. We noticed that some of the anti-inflammatory effects documented in that 
study are consistent with those we describe here.
Based upon our initial observations that NMP treatment enhanced Klf2 expression in a murine model of 
mesenchymal differentiation, our data shows that NMP exerts a dramatic and consistent set of anti-inflammatory 
effects across a broad range of cell culture, in vivo and ex vivo studies. A major translational finding of this study 
is our demonstration that NMP halts atherosclerotic progression in the ApoE−/− mouse model. This mouse, when 
fed with a high-fat diet, is the classical in vivo model used to study the early stages of atherogenesis. Since our 
data suggested that NMP influences the molecular and cellular processes involved in the initial inflammation and 
subsequent extra-vasation required for initiating atherogenesis, we reasoned that this would be an ideal in vivo 
model. Crucially, the ApoE−/− model has been used to demonstrate potential clinical efficacy for a number of 
current atherosclerosis  treatments49.
Recent advances in our understanding of the molecular basis of atherosclerosis offer new opportunities for 
therapeutic intervention. The concept that endothelial dysfunction both initiates and then promotes develop-
ment of atherosclerotic lesions is now well accepted. Therapeutic approaches targeting endothelial and pro-
inflammatory processes may therefore prevent the initiation, and indeed the progression, of the atherogenic 
process by promoting a return to vascular homeostasis. Central to the study presented here is the identifica-
tion and establishment of KLF2 as a master regulator of the anti-inflammatory  response12,59. Although initial 
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observation of Klf2 activation by NMP was shown in skeletal myoblasts C2C12 cell line, we also demonstrated 
that endothelial cells (MAEC and HUVEC cells) response in a similar way. This crucial body of evidence linking 
KLF2 expression to endothelial health and inflammation has led us to investigate the potential use of NMP as 
an anti-atherosclerotic agent.
Even though our initial transcriptomic approach uses only 2 mice per group, the consistency and the minor 
variability observed between samples set up the basis to demonstrate that NMP is able to activate KLF2 tran-
scriptional activity to blocks monocyte adhesion to endothelial cells and to reduce atherosclerosis development. 
Based on our in vitro and in vivo results, we show that NMP inhibits TNFα‐stimulated upregulation of VCAM1 
what end up in reducing monocyte adhesion to endothelial cells. As VCAM1 is a well‐known transcriptional 
target of KLF2, we investigated whether the downregulation of VCAM1 by NMP is KLF2-dependent15. In fact, 
KLF2 overexpression inhibits TNFα‐mediated induction of the proinflammatory molecule, such as VCAM1, 
in endothelial cells, what further supports that the mechanism for the antiatherosclerotic effect of NMP is at 
least partially attributed to KLF2‐dependent anti‐inflammatory activities. The consequent antiatherosclerotic 
effects accompanying KLF2 upregulation by NMP may include promoting a set of genes with demonstrated 
anti‐thrombotic, ‐inflammatory, and ‐proliferative functions. It is important to acknowledge that atherosclero-
sis is a complex chronic inflammatory disease which development depends on the functional interplay among 
multiple cell  types60. Given the fact that KLF2 is expressed in several cell types involved in atheroma plaque 
development, including monocyte/macrophage, endothelial cells, smooth muscle cells, and T cells,16,61,62 it is 
plausible that the atheroprotective effects of NMP is the result of that combined activity. We demonstrate in the 
ApoE−/− mouse model that NMP affects the inflammatory response of these cell types during the formation of the 
atherosclerotic lesion. Therefore, the precise contribution of distinct cell types in NMP‐mediated atheroprotec-
tion justifies future investigations.
The data presented here clearly demonstrates that NMP can halt atherosclerotic progression. We propose two 
possible translational routes for exploiting this finding. Firstly, NMP is a solvent which could be incorporated 
into many polymer-based biomaterials. One could therefore envisage its use in a drug-eluting stent, which might 
allow local delivery of NMP to the area of atherosclerotic plaques. Drug-eluting stents have been used exten-
sively, and with great success, in combination with anti-proliferative drugs such as  paclitaxel63 and  sirolimus64 
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Figure 8.  NMP attenuates THP‐1 monocyte adhesion to HUVECs. (a) Representative frames (from 
Supplemental Video 1) showing THP-1 cells adherence to a monolayer of TNF-α pre-activated HUVECs after 
treatment with NMP or saline. Numbers indicate elapsed time in minutes. (b) Quantitative analysis of the 
percentage of remaining attached THP-1 cells to the HUVEC monolayer by comparison of the percentage of 
attached cells at the beginning of the flow (time = 0 min). (c) Representative immunostaining of attached PBMC 
to a TNF-α activated HUVEC cells monolaye after 5 min of flow (5 dyn/cm2). PBMCs were stained with CD11b 
in green, and stressed endothelium with VCAM-1 (red), nuclei were stained with DAPI (blue). Merged images 
are also shown. (d) Quantitative analysis of VCAM-1/DAPI positive staining area from (c). Quantitative analysis 
of CD11b positive stained cells per field from (C). (n = 5; *p < 0.01, ***p < 0.001, unpaired Student’s t test).
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in order to prevent post-surgical restenosis. Given the effect of NMP on KLF2 levels, combining NMP with such 
compounds may provide an additional benefit by promoting a transcriptional profile associated with a healthy, 
non-inflamed endothelial and leukocytes.
Secondly, NMP has a well described safety and tolerability profile in the clinic as a solvent, and, therefore, 
might conceivably be considered for use in the formulation of statins, which are currently the favored medicine 
to lower plasma low-density lipoprotein (LDL) concentrations and to treat atherosclerosis. However, despite 
being fairly well tolerated, statins are associated with muscular symptoms, ranging from mild myalgia to rhab-
domyolysis. These side effects occur in up to 20% of statin users, and are a leading cause of non-compliance. Our 
data present the intriguing possibility of formulating statins with NMP to gain additional anti-atherosclerotic 
potential from this active solvent. In addition, it is possible that statin dose might be reduced if used in conjunc-
tion with NMP, thereby likely reducing side-effects and subsequent non-compliance. The data presented here 
clearly indicate that NMP warrants further investigation into its use to complement statin administration for 
the treatment of atherosclerosis.
Materials and methods
Animals. All experiments were carried out in accordance with the CNIC Institutional Ethics Committee 
recommendations, and were approved by the Animal Experimentation Committee of Comunidad de Madrid 
project number PROEX 019/17. Atherosclerosis mouse model and wild type control were maintained as pre-
viously  described65 with free access to food and water. Wild-type mice and homozygous ApoE-deficient mice 
(ApoE−/−), both on the C57BL/6 J genetic background were obtained from Charles River Laboratories. Mice were 
fed a low-fat standard rodent diet (Teklad global rat/mouse chow, Harlan Interfauna). When indicated, mice 
were switched to a high-fat diet containing 0.75% cholesterol (Ssniff, S8492-E010) and analyzed for atheroma 
plaque formation after 84 days. The mean daily  safe47 intake of NMP over the 12 weeks period was 150 mg/kg/
day administered in drinking water at 0.75 mg/ml. Mean daily water intakes in C57BL/6 J strain ranges from 
6-8 ml/day66 in 30 g body weight animals.
Microarray analysis. The murine myoblast C2C12 cell line (ATCC CRL-1772) was cultured in DMEM 
(Life Technologies 31966-021) supplemented with 10% Fetal Bovine Serum (Life Technologies 10270-106). Total 
RNA was extracted from cultured C2C12 cells using the RNeasy Mini Kit (Qiagen 74104) as directed by the 
manufacturer’s instructions. Microarray analysis on the murine C2C12 cell line was carried out by Geneservice 
Ltd (now Source Bioscience Ltd) using the AB1700 Mouse Genome Survey Array (Applied Biosystems). Analy-
sis was carried out on transcripts after 8 h of treatment with media only (untreated) or 5 mM NMP (Scharlau, 
ME0498). RNA amplification, labeling, hybridization, and detection were performed following the protocols 
supplied by Applied Biosystems together with the corresponding kits. The labeled RNAs were hybridized and 
detected according to the supplied protocols. All expression data was pre-processed and normalized. Differen-
tially Expressed Genes were identified from normalized data.
Gene knockdown assay and quantitative RT‑PCR. For stable knockdown of Klf2 gene cells were 
infected with shRNAs or EGFP control lentivirus in the presence of polybrene (8 μg ml−1). Lentiviral vector 
pGIPZ (Open Biosystems) was used to knockdown Klf2 (V3LMM_473116) expression, as well as a Non-silenc-
ing lentiviral shRNA was used as a control (NS; RHS4346). A multiplicity of infection (MOI) of 5 for 8 h was 
used for achieving over 95% transduction (GFP-positive) 72 h after infection. To target human KLF2 gene Stealth 
siRNA (HSS145585) was purchased from Life Technologies. Total RNA was extracted and reverse-transcribed 
from cultured C2C12, THP-1, or HUVECs (Life Technologies, C-003-5C) with the RNeasy Mini Kit (Qiagen 
74104) and SuperScript II cDNA synthesis kit (Life Technologies, 18064-014) according to the manufacturer’s 
instructions. RNA messenger was amplified on a Chromo4 RT-PCR System (BioRad) using the QuantiTect 
SYBR Green RT-PCR Kit (Qiagen 204243) following the manufacturer’s protocols. Primer sequences are listed 
in Supplementary Table 1. Expression was calculated comparing threshold cycle (CT) method and normalizing 
to Gapdh (mouse) or GAPDH (human) gene expression.
Klf2 Luciferase reporter assay. A 460 bp DNA fragment directly upstream of the Klf2 gene was amplified 
from mouse genomic DNA using the following primer sequences: Forward, 5′ GCC CCA AAC TTC ATC CTT 
CTT GTC 3′; Reverse, 5′ GCC TTA TAG GCG CGG CAG GCA CAG 3′. The resulting PCR product was cloned into 
the Firefly luciferase reporter vector pGL3Basic (Promega, E1751). The Klf2 reporter construct was transfected 
into C2C12 cells with the pRL-TK renilla luciferase normalization vector (Promega, E2241) using Lipofectamine 
2000 (Life Technologies 11668019) using supplied protocols. 24 h after transfection, luciferase levels were meas-
ured using the Dual-Glo Luciferase Assay System (Promega, E2940) as per manufacturer’s instructions using a 
BMG Labtech FluoStar plate reader. Firefly luciferase reporter data was normalized to the Renilla luciferase from 
the same well.
Apoptosis assay. Apoptosis in C2C12 myoblasts was assessed using the annexin V-FITC apoptosis detec-
tion kit (Sigma, Aldrich) in a 6-well plate format according to the manufacturer’s instruction. NMP activity was 
tested in the presence or absence of TNF-α (10 ng/ml) for 24 h. Cells were harvested, washed twice with cold 
PBS, and resuspended in annexin-V binding buffer at 1 × 105 cells/ml. A 250 μl aliquot of the mix was incubated 
with equal amounts (5 μl) of annexin-V and propidium iodide (PI, 20 μg/ml) in the dark at room temperature for 
15 min, before flow cytometer (BD Biosciences, USA) analysis. PI and annexin-V positive cells were considered 
as control live cells. Cells positive for annexin-V, negative or positive for PI were considered apoptotic, whereas 
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cells only PI positive were considered necrotic. The percent of apoptotic cells was calculated as the annexin-V 
positive cells relative to the overall number of cells.
cDNA library preparation and next generation sequencing (NGS). Samples were prepared and 
analyzed as previously  described67. Total RNA was quantified and purity checked using a NanoDrop ND-1000 
(Thermo Scientific). RNA integrity was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies). 
500 ng of total RNA were used with the TruSeq RNA Sample Preparation v2 Kit (Illumina, San Diego, CA) to 
construct index-tagged cDNA libraries. Libraries were quantified using a Quant-iT dsDNA HS assay with the 
Q-bit fluorometer (Life Technologies). Average library size and the size distribution were determined using a 
DNA 1000 assay in an Agilent 2100 Bioanalyzer. Libraries were diluted to 10 nM DNA content in 10 nM Tris–Cl, 
pH8.5, 0.1% Tween20. Libraries were applied to an Illumina flow cell for cluster generation (True Seq SR Cluster 
Kit V2 cBot) and sequence-by-synthesis single reads of 75 base length using the TruSeq SBS Kit v5 (Illumina) 
were generated on the Genome Analyzer IIx, using a standard RNA sequencing protocol. Reads were processed 
using CASAVA (Illumina) to split reads according to adapter indexes and produce fastq files. Read quality was 
determined by analyzing reads with FastQC.
NGS data and ingenuity pathway analysis. Reads (~ 10 M per sample) were mapped and gene expres-
sion calculated using RSEM  software68 over mouse assembly GRCm38 with genebuild version 70 from ensembl. 
Data from RSEM were then analyzed with the Bioconductor package  EdgeR69 using the generalized linear 
method. Probes selected by statistical analysis along with their differential expression value were loaded into 
Ingenuity Pathways Analysis software (IPA) (Ingenuity Systems) for annotation, redundancy checks, network 
and pathway analysis. Data was processed using IPA to the satisfaction of the right-tailed Fisher’s Exact Test, and 
significant networks based on semantic associations of these genes were generated.
Immunohistochemical analysis. Mouse hearts and aortas were processed and analyzed as previously 
 described65. Tissues were perfused with PBS, removed, fixed in 4% paraformaldehyde for 24 h, incubated for 
24 h in PBS supplemented with 30% sucrose, embedded in OCT and cryopreserved at -70 °C. Cryocut cross-
sections (5 μm) were then prepared. Samples were blocked for 30 min with 10% horse serum plus 2% BSA (for 
immunofluorescence) in PBS. Cryocut cross-sections were stained with Oil Red O (0.5% in isopropanol) or 
Masson’s trichrome stain. Images were acquired using an Olympus BX51 microscope using the fitted 10× or 
20× UPlanSApo objectives and Cell Sens Entry Ink acquisition software. Immunofluorescence samples were 
stained with rat anti-mouse CD68 F4/80 (AbD Serotec, MCA497R) and Cy3-conjugated mouse anti-smooth 
muscle actin (SMA) (Sigma-Aldrich, C6198). Images were acquired using an Olympus BX51 microscope fit-
ted with 10× or 20× UPlanSApo objectives and Cell Sens Entry Ink acquisition software. The secondary anti-
body for immunofluorescence was Alexa Fluor 633 goat anti-rat IgG (Invitrogen, A-21094). Nuclei were stained 
with DAPI. Immunofluorescence images were acquired using an inverted confocal microscope (Carl Zeiss Axio 
Imager Z2, Apotome.2) fitted with 20× or 40× HCX PL Apo oil immersion objectives and ZEN acquisition soft-
ware. Images were analyzed using ImageJ (http://rsbweb.nih.gov/ij/index.html) and were processed for presen-
tation with Adobe Photoshop.
ELISA. Cell culture media from HUVECs were harvested after the indicated treatment. MCP-1 and IL-6 
levels were measured by ELISA (BD Bioscience 559017 and 550799) according to the manufacturer’s supplied 
protocols.
Adhesion assay under static and flow conditions. THP-1 cells (1–5 × 106) were stained with calcein-
AM (Molecular probes) (10 μM) for 30 min at 37 °C after 3 consecutive serum-free RPMI washes. The staining 
was finished after washing cells in cold RPMI with 10% FBS. THP-1 cells resuspended in RPMI and 10% FBS 
were added to TNF-α (10 ng/ml) pre-activated HUVEC monolayers, and incubated for 30 min in the incuba-
tor. After RPMI repeated washes to remove unbound THP-1 cells the remaining cells were detached with 1 mM 
EDTA/PBS. Binding was quantified by flow cytometry, and expressed as the ratio of THP-1 (calcein-positive) to 
HUVEC cells (negative cells). Controls included stained and unstained THP-1 cells, non-labeled HUVECS and 
HUVECS incubated with the unbound labeled THP-1 cells.
All perfusions under steady flow were performed in µ-Slide  VI0.4 flow chambers (ibidi, 80601). The human 
promyelomonocytic cell line THP-1 (ATCC TIB-202) was cultured in RMPI 1640 (Life Technologies11875-093) 
supplemented with 10% FBS, 100U/mL penicillin and 100 μg/mL streptomycin (Life Technologies 15140-122). 
THP-1 cells and HUVECs were incubated for 6 h with 2.5 ng/ml TNF-α with or without 1 mM NMP before 
starting the flow (5.0 dyn/cm2). Videos were recorded for 3 min. Peripheral blood mononuclear cells (PBMCs) 
purchased from Lonza (Cat#CC-2702), were cultured in RPMI 1640 and 15%FBS at 37 °C and 5%CO2 before 
measuring adhesion to an endothelial monolayer under flow conditions. PBMCs (1 × 106 cells/ml) were added to 
confluent HUVECs which had been pre-stimulated with TNF-α (2.5 ng/ml) for 6 h. HUVECs were also incubated 
with 1 mM NMP where indicated. Individual 3 min runs of PBMCs were performed at 37 °C at a shear stress 
of 5.0 dyn/cm2. The adhered cells on the endothelial surface were quantified at the end of the perfusion time. 
The flow chamber was stained for VCAM-1 and CD11b. The shear stress is based on the dynamical viscosity of 
water at 22 °C, η = 0.01dyn·s/cm2, where t is shear stress; f, flow rate; h, dynamical viscosity. In µ-Slide  VI0.4 flow 
chambers, the shear stress follows the formula: t[dyn/cm2] = 1.316 f[ml/min].
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Statistical analysis. All the experimental outcomes have been analyzed blindly. Mouse experiments were 
designed to minimize the number of animals needed to give sufficient statistical power. No data were excluded 
from any analysis. All experiments have been repeated at least twice and with a minimum of two replicates. 
Statistical analyses were performed with GraphPad Software. Data are expressed as mean ± SEM, and results 
were analyzed by 1-way ANOVA with Bonferroni post hoc tests or by 2-tailed unpaired Student t test. Statisti-
cal significance of differences was assigned as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns 
p > 0.05.
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